Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QM6J | ISIN: US81728A1088 | Ticker-Symbol: 407
Tradegate
06.06.25 | 11:26
0,310 Euro
-0,32 % -0,001
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SENSEI BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SENSEI BIOTHERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3000,32006.06.
0,2950,32806.06.

Aktuelle News zur SENSEI BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoH.C. Wainwright stuft Sensei Biotherapeutics-Aktie mit "Kaufen" ein24
26.05.Research and Markets: VISTA Inhibitor Clinical Trials Market Insights and Drug Development Opportunities Report 2025-2028 Featuring Aurigene, Curis, Hummingbird Bioscience, Kineta, PharmAbcine, Sensei Biotherapeutics - ResearchAndMarkets.com294The "VISTA Inhibitor Clinical Trials, Drug Development Opportunities Patent Insight 2025" report has been added to ResearchAndMarkets.com's offering. The landscape of cancer immunotherapy has witnessed...
► Artikel lesen
23.05.Aktionäre von Sensei Biotherapeutics stimmen wichtigen Vorschlägen zu25
23.05.Sensei Biotherapeutics, Inc. - 8-K, Current Report6
SENSEI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
06.05.Sensei Biotherapeutics, Inc. - 10-Q, Quarterly Report9
06.05.Sensei Biotherapeutics GAAP EPS of -$0.2710
06.05.Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress174- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May...
► Artikel lesen
06.05.Sensei Biotherapeutics, Inc. - 8-K, Current Report1
28.03.Sensei Biotherapeutics GAAP EPS of -$1.2016
28.03.Sensei Rockets on FY '24 Results17
28.03.Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors8
28.03.Sensei Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
28.03.Sensei stock holds Buy rating, $4 target from H.C. Wainwright41
28.03.Sensei Biotherapeutics, Inc. - 10-K, Annual Report2
28.03.Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress164- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant "hot" tumor patient population - - Solnerstotug continues to demonstrate...
► Artikel lesen
27.03.Sensei Biotherapeutics, Inc. - 8-K, Current Report4
08.01.Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones492- Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics...
► Artikel lesen
07.01.Sensei Biotherapeutics, Inc. - 8-K, Current Report5
14.11.24Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights289- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - ...
► Artikel lesen
06.08.24Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights357- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - -...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1